Gary T. Choy, MBA
Co-Founder & Chief Executive Officer
Gary Choy is an accomplished pharmaceutical, biotech, and medical device executive with a proven ability to develop and commercialize novel therapeutics and devices across multiple therapeutic areas. He is an experienced launch expert with a unique combination of early and late stage commercialization experience. He has successfully taken molecules from discovery to full scale global launches.
Prior to joining f5, he was the Chief Commercial Officer at Calidi Biotherapeutics, a clinical stage oncolytic virus company. Prior to that he served as the Vice President of Marketing for Samumed LLC, where he built a commercial team overseeing the development of 7 Wnt-pathway clinical programs including osteoarthritis, oncology, Alzheimer’s Disease, tendinopathy, idiopathic pulmonary fibrosis, degenerative disc disease, and androgenetic alopecia.
Previously he has held various leadership roles at Johnson & Johnson including Global Marketing Leader for rheumatology, Head of U.S. marketing for Mentor Worldwide LLC, and Disease Area Strategy Leader for hepatitis C. Prior to that, he was a senior director of antivirals at Idenix Pharmaceuticals after holding various leadership positions in marketing and sales at Roche Pharmaceuticals and Abbott Laboratories. In these roles, Mr. Choy has been the commercial leader of several blockbuster brands including PEGASYS®, INCIVO®, OLYSIO®, REMICADE®, STELARA®, and SIMPONI®.
Mr. Choy received his B.S. from Rutgers College in marketing and biology and completed his MBA at Rutgers Graduate School of Management.
John Boylan, Ph.D.
John Boylan is a cell biology scientist by training focused on early oncology drug discovery. He has contributed to 12 development candidates, 8 compounds that have reached first-in-human clinical trials, and one approved drug, Zelboraf® (vemurafenib), a mutant BRAF inhibitor.
Prior to joining f5, Dr. Boylan was the Head of Discovery Oncology at Celgene where he was responsible for identifying and validating new drug targets and progressing selected targets into discovery and clinical development. He provided scientific assessments for new collaborations and alliances including Inhibrx, Presage, AnaptysBio, Oncomed, Forma, Moffitt, and Sutro.
Prior to Celgene, he held positions of increasing responsibility where he led the oncology drug discovery teams at Roche and Amgen. His focus was on small-molecule entities, therapeutic siRNA, and antibody modalities.
Dr. Boylan received his B.S. Degree from the University of Michigan and his Ph.D. from the University of Kentucky completing his post-doctoral training at Harvard Medical School. He is author on over 55 publications and patents.
Neil Raheja, Ph.D.
EVP Medicinal Chemistry
Dr. Raheja is an experienced drug hunter, medicinal chemist & entrepreneur with > 20 years of industrial experience. He has start-up experience as a founder of two San Diego based biotech companies (January Therapeutics & Venquis Therapeutics) and founder of independent drug discovery consulting firm (Integrated Pharma Solutions).
Dr. Raheja has extensive scientific, managerial, and leadership skills; and has worked in multiple
therapeutic areas including oncology, inflammation, immunotherapy, epigenetics, protein homeostasis, cardiovascular-metabolic diseases, dermatology, and CNS. Achievements include the delivery of 15 development candidates as a project/team leader, with 10 compounds reaching human clinical trials. Currently Dr. Raheja has 2 compounds in Ph 1/2.
Dr. Raheja received his Ph.D. from Wayne State University under the direction of Dr. Carl Johnson and completed his post-doctoral training as an NIH Postdoctoral Fellow in the labs of Dr. Amos B. Smith and the late Dr. Ralph Hirschmann. He is an author on > 50 patents and publications.
Allen Huang has over twenty years practicing before the New York and California bars. A seasoned general counsel with experience across corporate securities, capital markets, governance, compliance, IP, litigation and privacy, Mr. Huang has successfully managed Initial Public Offerings, complex mergers and acquisitions, IP portfolios and strategy, and legal threats in high-tech and other public company settings.
Prior to joining f5, Mr. Huang was the General Counsel at Swyft, Inc., a leader in retail automation and intelligence. Previously, Mr. Huang spent over eight years at Virgin America Inc., guiding the startup through mid- to late-stage financing, complex corporate restructurings, regulatory compliance, the Initial Public Offering and ultimate sale to Alaska Airlines. In earlier roles, Mr. Huang oversaw compliance and legal affairs as senior corporate attorney for semiconductor, real estate and securities trading companies.
Mr. Huang received his B.A. from Columbia University in political science and economics, and his J.D. from Brooklyn Law School. Mr. Huang is admitted to the New York and California Bars.
Cynthia Cai, （蔡小嘉） Ph.D.; MBA; M. Eng.
Dr. Cynthia Cai is an executive and investor with over twenty-five years of experience in the healthcare and life science industry. International experience in sales, marketing, business development, equity investment, and board membership. In-depth understanding of global biotech and life science business, widely recognized as having a unique ability to bridge collaborations between technology and business, between the west and east cultures.
Dr. Cai is currently a venture partner of Viva BioInnovator, investing in biotech innovation with novel solutions to cross multiple therapeutic areas. Before that, she served as senior advisor to Northern Light Venture Capital, led its healthcare investment effort in the US. She serves as a member of the board of f5 Therapeutics, Arthrosi Therapeutics, and AceLink Therapeutics.
Previously Dr. Cai had over 20 years of experience in leadership positions with Agilent Technologies. As senior director of marketing, she was responsible for its billion-dollar Chromatography, Automation, and Mass Spec. business. As business development and product marketing manager, she was involved in multiple acquisitions and divestitures, led a $500+ million-dollar flagship product development and its global commercialization, also led the company's first full IVD registration.
Dr. Cai earned a B.A. and Master of Engineering from Tsinghua University, received her Ph.D. in Chemistry from the University of Massachusetts, and an MBA from The Wharton Business School of the University of Pennsylvania. Dr. Cai had been a regular speaker at healthcare investment conferences such as BIO; RESI; China Focus at J.P. Morgan, SAPA Annual Conference, and Wharton China Business Forum.